Montelukast combined with loratadine treats allergic rhinitis by lowering the levels of serum trace elements, sIgE and ECP

Objective: To explore the efficacy of leukotriene receptor antagonist montelukast, combined with histamine receptor antagonist loratadine, in the treatment of patients with allergic rhinitis, and their effects on the levels of serum trace elements, specific immunoglobulin E (sIgE) and eosinophil cationic protein (ECP). Methods: A total of 104 patients with allergic rhinitis were divided into two groups using the computer-based random number method, namely a leukotriene receptor antagonist treatment group (Group M, n=52), and a leukotriene receptor antagonist combined with histamine receptor antagonist treatment group (Group A, n=52). The patients were compared in rhinitis score after treatment, levels of sIgE and ECP during treatment, related complications, and satisfaction. Results: After treatment, Group A got lower rhinitis score than Group M, and showed lower levels of serum sIgE and ECP, but higher satisfaction than Group M (all P<0.05), and Group A was not different from Group M in the incidence of complications (P>0.05). Conclusion: Leukotriene receptor antagonist combined with histamine receptor antagonist is more effective than leukotriene receptor antagonist alone for patients with allergic rhinitis, which may take effects by lowering the levels of serum trace elements, sIgE and ECP. It indicates that such a combination use of them is worthy of further promotion in clinical practice.